BioAge Labs, Inc. (BIOA)

Market Cap	220.11M
Revenue (ttm)	n/a
Net Income (ttm)	-70.94M
Shares Out	35.85M
EPS (ttm)	-33.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,182,714
Open	5.13
Previous Close	5.17
Day's Range	5.01 - 6.74
52-Week Range	3.85 - 26.62
Beta	n/a
Analysts	Hold
Price Target	18.00 (+193.16%)
Earnings Date	Feb 15, 2025

About BIOA

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 26, 2024
• Employees: 56
• Stock Exchange: NASDAQ
• Ticker Symbol: BIOA
• Website: https://bioagelabs.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 3 analysts, the average rating for BIOA stock is "Hold." The 12-month stock price forecast is $18.0, which is an increase of 193.16% from the latest price.

Price Target

$18.0

(193.16% upside)

Analyst Consensus: Hold